Wall Street expects a year-over-year decline in earnings on higher revenues when Ionis Pharmaceuticals (IONS) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on F ...

Ionis Pharmaceuticals, Inc. (IONS) announced that the FDA has granted a Fast Track designation to eplontersen for the treatment of adult patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).ATTR-CM is a progressive and fatal disease that is caused by the accumulation of misfolded TTR protein in the cardiac muscle.Ionis is developing eplontersen in partnership with British drugmaker AstraZeneca (AZN) .The phase III CARDIO-TTRansform study is currently evaluating eplontersen for treating ATTR ...

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults. The FDA grants development programs Fast Track designation to facilitate the development and expedite the review of drugs that demonstrate the potential to treat serio ...

Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results.The live webcast may be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ion ...

Ionis Pharmaceuticals (IONS) announced positive top-line results from the phase III OASIS-HAE study on its investigational drug donidalorsen in patients aged 12 years and older with hereditary angioedema (HAE).The OASIS-HAE study randomized study participants into three equal groups over a 24-week treatment period — two groups evaluating an 80mg dose of donidalorsen administered once every four weeks (Q4W) and another group wherein the drug was administered once every eight weeks (Q8W). The third group admi ...

Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks  Donidalorsen demonstrated a favorable safety and tolerability profile Ionis is preparing to submit a New Drug Application with U.S. FDA Data to be presented at an upcoming medical congress CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Pha ...

– Numerous value-driving commercial, regulatory and pipeline milestones anticipated – CARLSBAD, Calif., Jan. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 3pm PT; the presentation is available today on the Ionis website. In 2023, Ionis made sig ...

MicroStockHub Investment Overview The biotech sector of the stock market is finishing 2023 on a high after what has been a difficult couple of years. Buoyed by a Big Pharma M&A spree - the globally recognized Pharmas AbbVie (ABBV) and Bristol-Myers Squibb (BMY) have respectively spent a total of $18.8bn acquiring antibody drug conjugate ("ADC") specialist ImmunoGen (IMGN) and neuroscience pioneer Cerevel Therapeutics, and $18.1bn acquiring Karuna Therapeutics (KRTX) and its highly rated schizophrenia dr ...

U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life Additional regulatory reviews for WAINUA underway in rest of world WAINUA will be available in the U.S. in January 2024 CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ion ...

Brett Monia Operator Thank you very much for taking my question. With respect to Olezarsen given the recent pivotal data, as you look forward to severe hypertriglyceridemia, how -- I know that you achieved benefits with respect to pancreatitis, you received the reductions. But given the dynamics and differences in that population. How easy do you think it's going to be to show a pancreatitis benefit? My point is that our confidence has grown because the efficacy was so remarkable on reduction in AP events. ...